
Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

Santhera licences vamorolone rights to Catalyst Pharmaceuticals
Pratteln-based Santhera Pharmaceuticals Holding got a US$90m upfront payment from Catalyst Pharmaceuticals Inc for the Northern America vamorolone...

Enzyme foams morer active and stable
So far, foamed enzymes changed their structure and thus function. However, the new method, for which a patent has been filed circumvents this...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...

Mithra Pharmaceuticals SA in €17m licencing deal
Donesta is the first Estetrol-based hormone substitution therapy for the relief of menopausal vasomotor symptoms (VMS). Under a licencing deal with...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....